Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Beacon Therapeutics Launches with £96 million to Develop a New Generation of Gene Therapies
Beacon Therapeutics, a leading ophthalmic gene therapy company with a purpose to restore and improve […]
Astellas Submits New Drug Application for Zolbetuximab in Japan
Astellas Pharma has announced the submission of a New Drug Application (NDA) on June 9, […]
Gilteritinib as Maintenance Therapy Demonstrated Benefit in Subgroups of FLT3-ITD Acute Myeloid Leukemia Patients
Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) has presented […]
Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration
Charles River Laboratories International and the INADcure Foundation, a nonprofit organization whose mission is to […]
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas
Genmab has announced data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab, a T-cell […]
Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases
Quell Therapeutics, a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions […]
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430
Astellas Pharma and Kate Therapeutics have announced an exclusive license agreement to develop and commercialize KT430. […]
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals and CRISPR Therapeutics today announced that the United States Food and Drug Administration (FDA) […]
Sir Richard Roberts Elected to National Academy of Sciences
New England Biolabs (NEB®) has announced that Sir Richard Roberts, Nobel Prize winner and Chief […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more